PR-39 and PR-11 peptides inhibit ischemia-reperfusion injury by blocking proteasome-mediated IkBa degradation

Bao, Jialin, Kaori Sato, Min Li, Youhe Gao, Ruhul Abid, William Aird, Michael Simons, and Mark J. Post. PR-39 and PR-11 peptides inhibit ischemia-reperfusion injury by blocking proteasome-mediated IkBa degradation. Am J Physiol Heart Circ Physiol 281: H2612–H2618, 2001.— PR-39 inhibits proteasome-mediated IkBa degradation and might protect against ischemia-reperfusion injury. We studied PR-39, its truncated form PR-11, and a mutant PR11AAA, which lacks the ability to prevent IkBa degradation, in a rat heart ischemia-reperfusion model. After 30 min of ischemia and 24 h of reperfusion, cardiac function, infarct size, neutrophil infiltration, and myeloperoxidase activity were measured. Intramyocardial injection of 10 nmol/kg PR-39 or PR-11 at the time of reperfusion reduced infarct size by 65% and 57%, respectively, which improved blood pressure, left ventricular systolic pressure, and relaxation and contractility (6dP/dt) compared with vehicle controls 24 h later. Neutrophil infiltration, myeloperoxidase activity, and the expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule 1 were reduced. Thus PR-39 and PR-11 effectively inhibit myocardial ischemia-reperfusion injury in the rat in vivo. This effect is mediated by inhibition of IkBa degradation and subsequent inhibition of nuclear factor-kB-dependent adhesion molecules. The active sequence is located in the first 11 amino acids, suggesting a potential for oligopeptide therapy as an adjunct to revascularization.